Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2019

Open Access 01-12-2019 | Chronic Lymphocytic Leukemia | Letter to the Editor

Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study

Authors: Alice Ramassone, Andrea D’Argenio, Angelo Veronese, Alessio Basti, Shimaa Hassan AbdelAziz Soliman, Stefano Volinia, Cristian Bassi, Sara Pagotto, Manuela Ferracin, Laura Lupini, Elena Saccenti, Veronica Balatti, Felice Pepe, Laura Z. Rassenti, Idanna Innocenti, Francesco Autore, Laura Marzetti, Renato Mariani-Costantini, Thomas J. Kipps, Massimo Negrini, Luca Laurenti, Rosa Visone

Published in: Journal of Hematology & Oncology | Issue 1/2019

Login to get access

Abstract

Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse outcome, but also occurs in untreated patients, in which case its predictive role is debated. We investigated whether the selection and expansion of CLL clone(s) precede an aggressive disease shift. We found that clonal evolution occurs in all CLL patients, irrespective of the clinical outcome, but is faster during disease progression. In particular, changes in the frequency of nucleotide variants (NVs) in specific CLL-related genes may represent an indicator of poor clinical outcome.
Appendix
Available only for authorised users
Literature
1.
Sutton LA, Rosenquist R. Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. Haematologica. 2015;100(1):7–16.CrossRef
2.
Hernandez-Sanchez M, Kotaskova J, Rodriguez AE, Radova L, Tamborero D, Abaigar M, et al. CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. Leukemia. 2019;33(2):518–58.CrossRef
3.
Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, et al. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2019;33(2):390–402.CrossRef
4.
Rose-Zerilli MJ, Gibson J, Wang J, Tapper W, Davis Z, Parker H, et al. Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease. Leukemia. 2016;30(6):1301–10.CrossRef
5.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.CrossRef
6.
Mayrhofer M, Viklund B, Isaksson A. Rawcopy: improved copy number analysis with Affymetrix arrays. Sci Rep. 2016;6:36158.CrossRef
7.
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.CrossRef
Metadata
Title
Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study
Authors
Alice Ramassone
Andrea D’Argenio
Angelo Veronese
Alessio Basti
Shimaa Hassan AbdelAziz Soliman
Stefano Volinia
Cristian Bassi
Sara Pagotto
Manuela Ferracin
Laura Lupini
Elena Saccenti
Veronica Balatti
Felice Pepe
Laura Z. Rassenti
Idanna Innocenti
Francesco Autore
Laura Marzetti
Renato Mariani-Costantini
Thomas J. Kipps
Massimo Negrini
Luca Laurenti
Rosa Visone
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2019
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-019-0802-x

Other articles of this Issue 1/2019

Journal of Hematology & Oncology 1/2019 Go to the issue

Research

High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer

Correction

Correction to: Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells

Research

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Research

Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice

Research

SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer

Review

Targeting mTOR for cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits